Hoppa till innehål
banner-mesenkia-8

Almi Invest Invests in Mesenkia Therapeutics

New investment from Almi Invest

Mesenkia Therapeutics has received an investment from Almi Invest as part of a financing round totaling SEK 5.6 million.

The investment will support the continued development of Mesenkia’s novel therapeutic approach for glioblastoma and marks an important milestone for the company.

Read the full press release below for more information about the investment, the financing round, and Mesenkia’s continued development.

Read full press release here

More news

See all news

New Preclinical Findings Identify HVEM as a Promising Target in Aggressive Glioblastoma

Researchers have identified HVEM as a promising therapeutic target in mesenchymal glioblastoma...

Kohei Miyazono new member at the royal Swedish academy of science.

Kohei Miyazono has been elected as a new member to the Academy’s class for medical sciences at the royal ...

US Patent Application IP001 Receives Notice of Allowance

The US patent application IP001 has received an allowance for protection of our novel HVEM antagonistic single domain antibodies.

Cookiesamtycke

På webbplatsen används nödvändiga kakor för att webbplatsen ska fungera på ett bra sätt. Du kan även välja att samtycka till kakor för statistikinsamling.